In a recent well written, compelling article published in Nature Communications, “Endothelial activation of caspase-9 promotes neurovascular injury in retinal vein occlusion,” Avrutsky et al show that caspase-9 inhibition is a promising treatment for retinal vein occlusion. Retinal vein occlusion models hypoxic-ischemic neurovascular damage and is the second leading cause of blindness in working-age adults.
In Nature’s Scientific Reports, Becker et al use the Phoenix MICRON IV, OCT, and focal ERG to assess the therapeutic value of knocking down a splice variant of VEGF in Müller cells in a model of Retinopathy of Prematurity (ROP). ROP is characterized by delayed vascularization of the retina after disrupted oxygen levels, followed by
Corneal images taken with the Phoenix Micron IV OCT used for thickness analysis King et al, a consortium of researchers at a range of institutions, recently used the Phoenix Micron IV OCT to examine corneal thickness in their article, “Genomic locus modulating corneal thickness in the mouse identifies POU6F2 as a potential risk of developing
Monai et al characterized the longitudinal retinal degeneration of a rat model of retinitis pigmentosa using the Phoenix Micron OCT to examine retinal layers in live rats and the full field Ganzfeld ERG to test function. The rats have one of the mutations, P23H, that cause retinitis pigmentosa in humans, and are specifically a very